We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Novel Nanoparticles May Lead to Universal Antiviral Drug

By LabMedica International staff writers
Posted on 02 Jan 2018
A team of molecular virologists has developed a nanoparticle-based broad-spectrum antiviral agent that binds irreversibly to a large range of viruses and causes lethal structural deformations without affecting healthy tissue.

Available antiviral drugs are virus-specific and active against a limited panel of human pathogens. More...
There are broad-spectrum substances that prevent the first step of virus–cell interaction by mimicking heparan sulfate proteoglycans (HSPG), the highly conserved target of viral attachment ligands (VALs). However, the reversible binding mechanism prevents their use as a drug, because, upon dilution, the inhibition is lost. Known VALs are made of closely packed repeating units, but the aforementioned substances are able to bind only a few of them.

To avoid the reversible binding problem, investigators at Ecole Polytechnique Fédérale de Lausanne (Switzerland) designed antiviral nanoparticles with long and flexible linkers that mimicked HSPG. These novel nanoparticles simulated the VAL repeating units and enabled strong and multivalent viral association that eventually led to irreversible viral deformation.

The investigators reported in the December 18, 2017, online edition of the journal Nature Materials that the efficacy of this proposed mechanism was supported by virucidal assays, electron microscopy images, and molecular dynamics simulations. The particles showed no cytotoxicity, and in vitro irreversibly blocked the activity of herpes simplex virus (HSV), human papilloma virus, respiratory syncytial virus (RSV), dengue, and Lentivirus. In addition the particles were active in vitro in human cervicovaginal histocultures infected by HSV-2 and in vivo in mice infected with RSV.

Related Links:
Ecole Polytechnique Fédérale de Lausanne


New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
Serological Pipet Controller
PIPETBOY GENIUS
New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
New
Staining Management Software
DakoLink
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The RNA-seq based diagnostic test for pediatric leukemia ensures better outcomes for children with this common cancer (Photo courtesy of Qlucore)

RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia

A new unique test is set to reshape the way Acute Lymphoblastic Leukemia (BCP-ALL) samples can be analyzed. Qlucore (Lund, Sweden) has launched the first CE-marked RNA-seq based diagnostic test for pediatric... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.